CME Presentations




  • Kevin Brown, MD

    Kevin Brown, MD

    Kevin Brown, MD

    Professor and Chair, Department of Medicine

    Kevin K. Brown, MD, is a Professor and Chair, of the Department of Medicine at National Jewish Health. He has had a long-standing interest in the clinical and biologic aspects of fibrosing lung disease. Dr. Brown has had leadership positions in a number of national and international pulmonary organizations, and serves on the steering and protocol development committees of multiple national and international multi-centered treatment trials in lung fibrosis. He maintains an active clinical practice as well as a translational research program focused on the development, progression, and control of fibrosing lung diseases.
  • Kevin Flaherty, MD

    Kevin Flaherty, MD

    Kevin Flaherty, MD

    Professor of Internal Medicine Michigan Medicine Pulmonary Clinic | Taubman Center

    Dr. Kevin R. Flaherty is a Professor of Medicine in the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine at the University of Michigan in Ann Arbor, Michigan. Dr. Flaherty is the director of the Interstitial Lung Disease program, serves as Vice-Chair of the Medical School Institutional Review Board for Human Subjects Research and is the steering committee chair for the pulmonary fibrosis foundation’s Care Center Network and Patient Registry. His clinical and research interests center around the diagnosis, monitoring, and care of patients with interstitial lung diseases. He is an active participant on grants and clinical trials related to the study and treatment of patients with idiopathic interstitial pneumonias, particularly idiopathic pulmonary fibrosis.
  • Rebecca Keith, MD

    Rebecca Keith, MD

    Rebecca Keith, MD

    Associate Professor, Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine

    Rebecca C. Keith, MD is an Associate Professor in the Division of Pulmonary, Critical Care and Sleep Medicine at National Jewish Health and University of Colorado Health Sciences Center. She is the medical director for Outpatient Pulmonary Clinics at National Jewish Health. Dr. Keith earned her medical degree at The Weill Medical College of Cornell University in New York, NY. She completed her residency and chief residency in Internal Medicine at Emory University School of Medicine in Atlanta, GA, followed by her fellowship in Pulmonary and Critical Care Medicine at the University of Colorado School of Medicine in Aurora, CO. Dr. Keith aims to contribute to the understanding of the pathogenesis of Idiopathic Pulmonary Fibrosis and autoimmune lung disease via basic, translational, and clinical research with the ultimate aim to improve quality of life for patients with pulmonary fibrosis. She has a strong interest in autoimmune lung disease and the intersection between innate immunity and the development of fibrotic lung disease.

CME Information

Emerging Treatments: Diagnosis and Treatment of Chronic Fibrosing ILD with a Progressive Lung Disease Phenotype

NJH LogoPQH Logo

Educational Objectives

Upon completion of the educational activity, participants should be able to:
  • Define PF-ILD, identify conditions associated with PF-ILD, and describe the impact of PF-ILD on symptoms, pulmonary function, and mortality.
  • Describe best practices for the early and accurate diagnosis of PF-ILD and the follow-up of patients with ILDs who are at risk for developing PF-ILD.
  • Discuss evidence-based strategies and emerging therapies for the pharmacologic treatment of PF-ILD.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Program Description

The goal of this activity is to improve the awareness, knowledge, and competency of pulmonologists, rheumatologists, radiologists, dermatologists and primary care physicians in the diagnosis, treatment and a multidisciplinary approach to the longitudinal management of Systemic Sclerosis Interstitial Lung Disease (SSc-ILD).

AMA PRA Category 1 Credits

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

National Jewish Health designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest Policy:

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, CME approval committee, and those in position to control the content of this activity disclose any relevant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.

All CME educational activities sponsored by National Jewish Health are reviewed by our faculty CME committee to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.

Target Audience

Pulmonologists, Radiologists, and Pathologists, as well as Primary Care Physicians, Nurse Practitioners, and Physician Assistants.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.


National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

Faculty and Disclosure

Kevin Brown, MD
Professor and Chair
Department of Medicine
National Jewish Health
Denver, CO

Kevin R. Flaherty, MD
Professor of Internal Medicine
Michigan Medicine Pulmonary Clinic | Taubman Center
University of Michigan
Ann Arbor, MI

Rebecca C. Keith, MD
Associate Professor
Department of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
Interstitial Lung Disease Program
National Jewish Health
Denver, CO

Kevin Brown, MD discloses grants from NHLBI and the Open Source Imaging Consoritum (OSIC), personal fees from Biogen, Galecto, Third Pole, Galapagos, Boehringer Ingelheim, Theravance, Lifemax, Pliant, Blade Therapeutics, Huitai Biomedicine, Lilly, Dispersol, DevPro Biopharma, and Humanetics outside the submitted work.

Kevin Flaherty, MD discloses that he is a consultant for Bellerophon, Boehringer Ingelheim, Respivant, and Shionogi.

Rebecca Keith, MD discloses that she is a speaker for Boehringer Ingelheim and Genentech.

None of the following planners or reviewers have any relevant financial relationships to disclose: Amen Sergew, MD, Michael Mohning, MD, Andrea Harshman, MHA, CHCP, CMP-HC, Meghan Brenner, MA, Mandy Comeau, the patient featured in the video segment.


In order to receive CME credits, participants must complete the pre-assessment questions, post-test, and program evaluation. Participants must also score 2 out of 3 on the posttest. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact

NJH Privacy Policy

The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).

We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.

If you decide to register for an Internet CME program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME activities.

Technical Support: For any technical issues or issues with your CME Certificate, please contact at 877-394-1306 or at